Bristol Myers Squibb (BMY) Expected to Release Earnings on Thursday

Key Points

• Bristol Myers Squibb is expected to report Q3 2026 results on October 29 before the market opens, with analysts forecasting $1.10 in earnings per share and $12.74 billion in revenue.
• The company exceeded expectations in its latest quarter, reporting $2.04 EPS versus the $1.60 consensus and $12.97 billion in revenue, up 5.7% year over year.
• BMY recently declared a quarterly dividend of $0.63 per share, equivalent to a $2.52 annualized payout and a 4.1% yield; analysts maintain a “Moderate Buy” consensus with a $64.88 price target.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) is projected to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Bristol Myers Squibb to post earnings of $1.10 per share and revenue of $12.74 billion for the quarter. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Individuals can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm's revenue was up 5.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.46 EPS. On average, analysts expect Bristol Myers Squibb to post $6.56 EPS for the current fiscal year and $6.50 EPS for the next fiscal year.

Bristol Myers Squibb Trading Down 0.8%

NYSE BMY opened at $61.17 on Thursday. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The firm has a market capitalization of $124.95 billion, a P/E ratio of 13.47, a PEG ratio of 0.31 and a beta of 0.19. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $68.64. The business has a fifty day simple moving average of $63.34 and a 200 day simple moving average of $60.30.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 55.51%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm's stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president directly owned 16,862 shares of the company's stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on BMY shares. Zacks Research upgraded shares of Bristol Myers Squibb from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, September 23rd. Raymond James Financial started coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "strong-buy" rating on the stock. Cantor Fitzgerald lowered their price target on shares of Bristol Myers Squibb from $59.00 to $53.00 and set a "neutral" rating for the company in a research note on Thursday, October 8th. BMO Capital Markets reiterated a "market perform" rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Finally, Rothschild & Co Redburn raised their price objective on shares of Bristol Myers Squibb from $51.00 to $53.00 and gave the stock a "neutral" rating in a report on Thursday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of "Moderate Buy" and a consensus price target of $64.88.

About Bristol Myers Squibb

Bristol Myers Squibb NYSE: BMY is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company's portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.